Table 3.
Grade ≥3 TEAEs reported in ≥5% of patients with B-NHL who received loncastuximab tesirine (safety analysis set)
| TEAE | n (%) | ||||
|---|---|---|---|---|---|
| ≤90 µg/kg (n = 17) | 120 µg/kg (n = 42) | 150 µg/kg (n = 88) | 200 µg/kg (n = 36) | Total (N = 183) | |
| Any | 9 (52.9) | 32 (76.2) | 69 (78.4) | 31 (86.1) | 141 (77.0) |
| Neutrophil count decreased* | 6 (35.3%) | 12 (29.3) | 35 (40.7) | 18 (51.4) | 71 (39.7) |
| Platelet count decreased* | 1 (5.9%) | 7 (17.1) | 25 (28.7) | 15 (42.9) | 48 (26.7) |
| GGT increased | 4 (23.5) | 9 (21.4) | 15 (17.0) | 11 (30.6) | 39 (21.3) |
| Anemia | 3 (17.6) | 4 (9.5) | 16 (18.2) | 5 (13.9) | 28 (15.3) |
| Blood ALP increased | 4 (23.5) | 3 (7.1) | 3 (3.4) | 2 (5.6) | 12 (6.6) |
| Lymphocyte count decreased | 0 | 4 (9.5) | 6 (6.8) | 2 (5.6) | 12 (6.6) |
| PD | 0 | 2 (4.8) | 9 (10.2) | 0 | 11 (6.0) |
| Febrile neutropenia | 1 (5.9) | 2 (4.8) | 6 (6.8) | 1 (2.8) | 10 (5.5) |
| Hypokalemia | 0 | 0 | 8 (9.1) | 2 (5.6) | 10 (5.5) |
ALP, alkaline phosphatase.
*
Platelet count decreased and neutrophil count decreased are based on laboratory abnormality reporting; data for 4 patients (1 at 120 µg/kg, 2 at 150 µg/kg, and 1 at 200 µg/kg) were missing for neutrophil count decreased, and data for 3 patients (1 each at 120, 150, and 200 µg/kg) were missing for platelet count decreased.